Another Bad Day For Boston Scientific (BSX)
The bad days never seem to end at Boston Scientific (NYSE: BSX). The company has a heavy debt load from a bad acquisition of Guidant. The BSX stent business has been hurt by studies that question the safety of the…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The bad days never seem to end at Boston Scientific (NYSE: BSX). The company has a heavy debt load from a bad acquisition of Guidant. The BSX stent business has been hurt by studies that question the safety of the devices.
Now the company has been told by a court that it must pay $431 million to a doctor who holds patents on certain IP in BSX drug-coated stents. According to the AP, Boston Scientific "plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal."
With the company’s luck that is not likely.
BSX shares trade just above $12, near their 52-week low and down from the period high of $17.32.
Douglas A. McIntyre
ro
Contact [email protected] for any questions or corrections.